Slow, but complete, resolution of mitomycin-induced refractory thrombotic thrombocytopenic purpura after rituximab treatment.

Korean J Hematol 2011 Mar 15;46(1):45-8. Epub 2011 Mar 15.

Division of Hematology-Oncology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.

Thrombotic thrombocytopenic purpura (TTP) is a critical complication of treatment with mitomycin C. We retrospectively describe the case of a patient with progressive renal cell carcinoma and mitomycin-induced TTP refractory to plasma exchange and glucocorticoids; we describe the clinical course, successful management of TTP with rituximab, and follow-up of this case. Mitomycin-induced TTP resolved completely by a total of 4 infusions of rituximab 375 mg/m(2) on a weekly basis, and it took up to 12 months to obtain a platelet count of >100,000/µL. Rituximab is indicated for the treatment of mitomycin-induced TTP refractory to plasma exchange and glucocorticoids, and it could improve the patient's quality of life despite the presence of underlying malignancy.

Download full-text PDF

Source
http://dx.doi.org/10.5045/kjh.2011.46.1.45DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065627PMC
March 2011
11 Reads

Publication Analysis

Top Keywords

mitomycin-induced ttp
12
exchange glucocorticoids
8
thrombocytopenic purpura
8
plasma exchange
8
refractory plasma
8
ttp refractory
8
thrombotic thrombocytopenic
8
ttp
5
clinical course
4
describe clinical
4
patient's quality
4
improve patient's
4
course successful
4
management ttp
4
successful management
4
glucocorticoids describe
4
count >100000/µl
4
carcinoma mitomycin-induced
4
months platelet
4
basis months
4

Similar Publications